Press Releases Year None202320222021202020192018 Mar 30, 2023 Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants Feb 27, 2023 Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Feb 21, 2023 Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants Feb 16, 2023 Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 Feb 07, 2023 Vaxcyte to Present at the SVB Securities Global Biopharma Conference Jan 05, 2023 Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Displaying 21 - 26 of 26
Year None202320222021202020192018 Mar 30, 2023 Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants Feb 27, 2023 Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Feb 21, 2023 Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants Feb 16, 2023 Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 Feb 07, 2023 Vaxcyte to Present at the SVB Securities Global Biopharma Conference Jan 05, 2023 Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Displaying 21 - 26 of 26
